NASDAQ · NEO
Healthcare · Medical - Diagnostics & Research
$17.38
Down-$0.08 (-0.46%)
Updated Sep 5, 2026, 7:54 AM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
NEO closed at $17.38 after 21 trading sessions, up 4.89% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $17.20 | $17.47 | $16.865 | $17.38 | 997.01K |
| Sep 3, 2026 | $17.50 | $17.90 | $17.0542 | $17.46 | 2.25M |
| Sep 2, 2026 | $17.40 | $18.1763 | $17.26 | $17.40 | 1.79M |
| Sep 1, 2026 | $17.67 | $18.105 | $17.359 | $17.45 | 1.32M |
| Aug 31, 2026 | $17.77 | $18.075 | $17.19 | $17.91 | 1.58M |
| Aug 28, 2026 | $18.36 | $18.75 | $17.8938 | $18.05 | 1.72M |
| Aug 27, 2026 | $17.85 | $19.76 | $17.85 | $18.64 | 5.1M |
| Aug 26, 2026 | $16.69 | $17.455 | $16.58 | $17.37 | 1.68M |
| Aug 25, 2026 | $16.70 | $16.90 | $16.37 | $16.79 | 872.11K |
| Aug 24, 2026 | $16.75 | $16.80 | $16.28 | $16.41 | 1.1M |
| Aug 21, 2026 | $16.60 | $17.075 | $16.21 | $16.98 | 1.14M |
| Aug 20, 2026 | $16.18 | $16.82 | $15.98 | $16.53 | 2.75M |
| Aug 19, 2026 | $16.20 | $16.70 | $16.08 | $16.655 | 1.56M |
| Aug 18, 2026 | $16.04 | $16.3038 | $15.75 | $15.90 | 936.59K |
| Aug 17, 2026 | $15.72 | $16.36 | $15.72 | $16.16 | 1.14M |
| Aug 14, 2026 | $16.38 | $16.395 | $15.89 | $15.94 | 906.01K |
| Aug 13, 2026 | $16.51 | $16.66 | $16.32 | $16.39 | 956.24K |
| Aug 12, 2026 | $16.40 | $16.58 | $16.243 | $16.42 | 1.05M |
| Aug 11, 2026 | $16.755 | $16.80 | $16.37 | $16.53 | 3.72M |
| Aug 10, 2026 | $16.53 | $16.92 | $16.33 | $16.63 | 1.95M |
| Aug 7, 2026 | $15.86 | $16.60 | $15.86 | $16.57 | 1.35M |
The latest Smart Investors Daily articles mentioning NEO.
NEO research
Company profile and research snapshot.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 29, 2026 | Needham | Buy | — |
| Jul 24, 2026 | Benchmark | Buy | — |
| Apr 29, 2026 | TD Cowen | Buy | — |
| Apr 29, 2026 | Benchmark | Buy | — |
| Apr 29, 2026 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 26, 2026
New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuumNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions
Benzinga · Aug 25, 2026
Greenland Mines released an Initial Assessment for its Sarfartoq project, projecting a pre-tax net present value up to $2.05 billion.
Yahoo · Aug 25, 2026
Maiden S-K 1300 economic study represents only the ST1 Nd-Pr rare earth deposit within the Sarfartoq REE carbonatite district At 2025 consumption levels, the NdPr oxide Sarfartoq is expected to produce annually from ST1 alone would represent approximately 34% of all NdPr oxide refined outside China CHARLOTTE, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- via IBN – Greenland Mines Ltd (Nasdaq: GRML) ("Greenland Mines" or the "Company"), a Western-aligned critical minerals developer, today announced tha
Yahoo · Aug 25, 2026
Neo Performance Materials (TSX:NEO) is back in focus after releasing second quarter 2026 results that showed higher sales, net income and earnings per share from continuing operations compared with the same period last year. See our latest analysis for Neo Performance Materials. The earnings release comes after a strong run for Neo Performance Materials, with the year to date share price return of 96.63% and a 1 year total shareholder return of 97.08%. However, shorter term momentum has...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NEO.
